Down Syndrome clinical trials at UCSD
1 research study open to new patients
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome
open to eligible people ages 25-45
The purpose of this study is to test in adults with Down Syndrome the safety, tolerability and immunogenicity of a vaccine, ACI-24.
La Jolla, California and other locations
Last updated: